Emcure Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE168P01015
  • NSEID: EMCURE
  • BSEID: 544210
INR
1,395.85
-8.4 (-0.6%)
BSENSE

Dec 05

BSE+NSE Vol: 87.03 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Neuland Labs.
Emcure Pharma
J B Chemicals &
Astrazeneca Phar
Ipca Labs
Pfizer
Ajanta Pharma
Gland Pharma
Wockhardt
Piramal Pharma
Anthem Bioscienc
Why is Emcure Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROCE of 21.37%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.69 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.80% of over the last 5 years
4
The company has declared Positive results for the last 5 consecutive quarters
  • DPS(Y) Highest at Rs 3.00
  • NET SALES(Q) Highest at Rs 2,269.82 cr
  • PBDIT(Q) Highest at Rs 475.47 cr.
5
With ROCE of 21.4, it has a Expensive valuation with a 4.7 Enterprise value to Capital Employed
  • Over the past year, while the stock has generated a return of 1.97%, its profits have risen by 36%
6
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 1.96% over the previous quarter and collectively hold 7.66% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Emcure Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Emcure Pharma for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Emcure Pharma
2.01%
0.05
39.54%
Sensex
4.78%
0.39
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
14.90%
EBIT Growth (5y)
8.80%
EBIT to Interest (avg)
6.91
Debt to EBITDA (avg)
1.10
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
1.28
Tax Ratio
27.01%
Dividend Payout Ratio
0
Pledged Shares
0.04%
Institutional Holding
7.66%
ROCE (avg)
18.86%
ROE (avg)
16.94%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
33
Industry P/E
34
Price to Book Value
5.61
EV to EBIT
22.06
EV to EBITDA
16.76
EV to Capital Employed
4.71
EV to Sales
3.29
PEG Ratio
NA
Dividend Yield
0.21%
ROCE (Latest)
21.37%
ROE (Latest)
16.94%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company
DPS(Y)

Highest at Rs 3.00

NET SALES(Q)

Highest at Rs 2,269.82 cr

PBDIT(Q)

Highest at Rs 475.47 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 20.95%

PBT LESS OI(Q)

Highest at Rs 338.30 cr.

PAT(Q)

At Rs 243.46 cr has Grown at 29.0% (vs previous 4Q average

EPS(Q)

Highest at Rs 12.84

-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Emcure Pharma
Net Sales - Quarterly
Highest at Rs 2,269.82 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 475.47 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 20.95%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 338.30 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 338.30 cr has Grown at 31.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 257.01 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 243.46 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 243.46 cr has Grown at 29.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 188.66 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 12.84
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Dividend per Share (DPS) - Annually
Highest at Rs 3.00
in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (Rs)